Pfizer Inc
NYSE: PFE
▼
35.96
-0.01
-0.03%
1 Day
-
Open
36.10
-
Previous Close
35.97
-
Volume (Avg)
14.61M (17.18M)
-
Day's Range
35.77-36.12
-
52Wk Range
29.83-36.21
-
Market Cap.
213.87B
-
Dividend Rate (Yield)
1.28 (3.56%)
-
Beta
1.01
-
Shares Outstanding
5.95B
-
P/E Ratio (EPS)
26.25 (1.37)
Top Stories
-
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
Seeking Alpha 1 day agoThe VanEck Vectors Biotech ETF is discussed. Esperion's potential in the statin-intolerant anti-cholesterol market is discussed. Pfizer’s BAVENCIO (avelumab) is approved in Europe for the treatment of adult patients with metastatic Merkel cell carcinoma.
-
Pfizer sues Johnson & Johnson over Remicade biosimilar
CNBC -
Pfizer takes on J&J with antitrust lawsuit
Financial Times -
Pfizer Announces Positive Late Stage Trial of Cancer Treatment
The Street -
Pfizer to test drug for liver disease linked to rising obesity
Financial Times 2 days ago -
General Electric Takes Over #19 Spot From Pfizer
The Street -
Pfizer prostate cancer drug succeeds key trial
The Irish Times -
Pfizer files suit against J&J over Remicade contracts
androidevo.com -
Pfizer-J&J Legal Brawl Could Set Precedent For Competition In Biosimilar Landscape
khn.org -
Pharma Stock Roundup: Pfizer Files Suit Against J&J, Supernus Hit By Study Update
investing.com -
Back to School with Pfizer $25 Visa #Giveaway
raisingthreesavvyladies.com -
Pfizer Inc. (PFE) Closes 0.03% Down on the Day for September 22
Equities -
Global Urinary Tract Infection Therapeutics Market 2017 Top Players : Pfizer, Novartis International, Johnson & Johnson, Cipla
sbwire.com -
Pfizer, Veritas, MGH Join Xconomy’s Healthcare + A.I. Conference on Nov. 2
Xconomy -
Pfizer Sues J&J Over Contracts Blocking Remicade Biosimilars
raps.org 1 day agoRAPS Virtual Career Fairs are designed to connect employees with employers no matter where they might be located. Local or global—RAPS has you covered with offices in Washington, DC, Shanghai and Singapore. There are RAPS chapters in Canada, Israel ...
-
FDA advisers split on new kidney cancer use for Pfizer’s Sutent
pharmaphorum.com -
Merck, Pfizer get EC approval for skin cancer drug Bavencio
PBR Regulatory Affairs -
Global Biosimilar Market 2017 top players : Merck, Amgen, Roche, Pfizer
qwtjlive.com
